



Oscillating Positive
Expiratory Pressure Therapy System

**Empowering COPD Patients** to Breathe Better,
Live Better by Reducing
Exacerbations<sup>4</sup>

**77%** of COPD patients have experienced an exacerbation leading to an increased risk of hospitalization and disease progression.<sup>1</sup>

What are you interested in learning about?

1. Neil Barnes et al; COPD and exacerbations: Patient insights. BMC Pulmonary Medicine 2013. 4. Burudpakee et al; Pulm Ther 2017 DOI: 10.1007/s41030-017-0027-5.

## The countdown to her next COPD exacerbation has already begun



#### Globally COPD is...



**3rd** leading cause of death<sup>2</sup>



<sup>+</sup>251 million



+3 million

#### Acute exacerbations result in:

- Decline in lung function<sup>3</sup>
- Poorer quality of life<sup>3</sup>
- Increased mortality<sup>3</sup>
- Frequent hospital admissions, relapses and readmissions<sup>3</sup>


1 in 5 patients hospitalized for a COPD exacerbation require rehospitalization within 30 days4

#### **Reduces COPD exacerbations**


#### by 28% in the critical 30 day period<sup>4</sup>

Real world study measured the rate of early (30-day) moderate-to-severe exacerbations and related costs in COPD patients with chronic bronchitis.

Moderate-to-severe exacerbation is defined as a hospitalization or an emergency department visit.



#### Improves **Quality of Life** in **COPD Patients**<sup>5</sup>




- † Randomized cross-over study evaluating fourtimes daily *Aerobika*\* device use after 3-4 weeks of treatment in COPD patients with chronic bronchitis.
- ‡ Clinical assessment of COPD patients with chronic bronchitis over 8 weeks of treatment with the *Aerobika\** OPEP device.
- St. George's Respiratory Questionnaire (SGRQ) measures impact on overall health, daily life and perceived well-being in airways disease; MCID≥4 COPD Assessment Test (CAT) assesses impact of COPD on health status; MCID≥2

#### Improves **Ventilation** in COPD Patients<sup>6</sup>

**BEFORE**Baseline care (no OPEP/PEP device)

**AFTER**Baseline care plus *Aerobika\** device




Teal colour and intensity show areas with gas distribution. Yellow circles represent areas of greatest change after 3-4 weeks of *Aerobika\** device use.

Randomized cross-over study evaluating four-times daily **Aerobika\*** device use after 3-4 weeks of treatment in COPD patients with Chronic bronchitis Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) ventilation in representative sputum producer.

# Mevers et al: A lab assessment of different OPEP device CHEST 20:

#### **Efficiency** and **Effectiveness**<sup>7</sup>

The **Aerobika**\* OPEP device was the most efficient and effective OPEP device tested **in vitro**<sup>7</sup>



Prescribe the **Aerobika**\* device as an add-on to usual COPD treatment.

# 8. J. Suggett et al; A retrospective cohort study comparing 2 OPEP devices in patients with COPD. ATS 2

### Aerobika\* OPEP Device and Acapella<sup>†</sup> device comparison<sup>8</sup>

n=619 **Aerobika**\* OPEP Device n=1857 Acapella† device

Real world evidence among Chronic Obstructive Pulmonary Disease (COPD) patients with chronic bronchitis on Hospital Readmissions at 30 Days and 12 Months

